Although radixin is reported to play a role in pancreatic cancer progression [52], its essential role in regulating the transmembrane molecule PD-L1 could lead to success in targeting pancreatic cancer by immunotherapy with PD-L1 antibody in the presence of kinase inhibitors such as AT or WZ, which increase radixin. This evidence concerns the gene RDX and familial pancreatic carcinoma.